Evidence map›Paper›PMID 35718064›Full record

SynthesisCritical reviews in oncology/hematology2022

Evidence of brain-derived neurotrophic factor in ameliorating cancer-related cognitive impairment: A systematic review of human studies.

Ding Quan Ng, Daniella Chan, Parisa Agrawal, Weian Zhao, Xiangmin Xu, Munjal Acharya, Alexandre Chan

Open access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Critical reviews in oncology/hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. BDNF Augmentation Using Riluzole Reverses Doxorubicin-Induced Decline in Cognitive Function and Neurogenesis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ding Quan NgDepartment of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, CA, USA; Department of Pharmaceutical Sciences, School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, CA, USA.
Daniella ChanDepartment of Pharmaceutical Sciences, School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, CA, USA.
Parisa AgrawalDepartment of Pharmaceutical Sciences, School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, CA, USA.
Weian ZhaoDepartment of Pharmaceutical Sciences, School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, CA, USA; Department of Biological Chemistry, School of Medicine, University of California Irvine, Irvine, CA, USA; Department of Biomedical Engineering, The Henry Samueli School of Engineering, University of California Irvine, Irvine, CA, USA; Institute for Immunology, University of California Irvine, Irvine, CA, USA; Sue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, USA; Edwards Life Sciences Center for Advanced Cardiovascular Technology, University of California Irvine, Irvine, CA, USA; Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA.
Xiangmin XuDepartment of Anatomy and Neurobiology, School of Medicine, University of California Irvine, Irvine, CA, USA; The Center for Neural Circuit Mapping, University of California Irvine, Irvine, CA, USA.
Munjal AcharyaDepartment of Anatomy and Neurobiology, School of Medicine, University of California Irvine, Irvine, CA, USA; Department of Radiation Oncology, School of Medicine, University of California Irvine, Irvine, CA, USA.
Alexandre ChanDepartment of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, CA, USA; Department of Pharmaceutical Sciences, School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, CA, USA; Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA. Electronic address: a.chan@uci.edu.
University of California, Irvine · US

Funding

Neurotrophic strategy to mitigate chemotherapy-related brain injuryR01CA276212 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Munjal M Acharya, Alexandre Chan · 2023 to 2026
$1.9M
NCI NIH HHS R01 CA276212
6 · The paper itself

Abstract

Brain-derived neurotrophic factor (BDNF) plays an essential role in neurogenesis and neuroplasticity and may be a key protein in cancer-related cognitive impairment (CRCI). This systematic review assessed the relationship between BDNF biomarkers and neurocognitive outcomes in cancer patients and survivors. A search in PubMed, Scopus, and PsycINFO yielded 638 articles, of which 26 were eligible. Fourteen (54 %) studied BDNF protein levels while 15 (58 %) analyzed BDNF rs6265 polymorphism. Of the nine observational studies reporting BDNF plasma/serum levels, five (56 %) exhibited a positive association between BDNF and cognitive function. One study reported intra-tumoral BDNF levels that were negatively associated with memory. For rs6265, three (20 %) of 15 studies reported an association with cognitive function with inconsistent directions. Among seven neuroimaging studies, three (43 %) demonstrated an effect of BDNF on brain function and structure. These results suggest that BDNF is a potential monitoring biomarker and druggable target for CRCI.

Indexed as

Cognitive DysfunctionNeoplasmsBiomarkersBrain-Derived Neurotrophic FactorCognitionHumansPolymorphism, GeneticBiomarkersBrain-Derived Neurotrophic FactorBDNFBiomarkerChemotherapyCognitionMemory

Identifiers

PMID35718064
PMCPMC12678231
OpenAlexW4283025624

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.